|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Introgen Therapeutics |
|---|---|
| Information provided by: | Introgen Therapeutics |
| ClinicalTrials.gov Identifier: | NCT00041613 |
Purpose
There is a need for more treatment options for patients with recurrent squamous cell cancer of the head and neck (SCCHN). These tumors usually have a variety of genetic defects that include disruption of the p53 pathway, a pathway that would ordinarily work to prevent the development of tumors. In this study the transfer of the p53 gene to tumor cells using a modified adenovirus (INGN 201) will be compared to methotrexate in patients who have failed surgery, radiotherapy and chemotherapy with platinum or taxanes.
| Condition | Intervention | Phase |
|---|---|---|
|
Carcinoma, Squamous Cell |
Genetic: INGN 201 |
Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Contacts and Locations| Contact: Introgen Therapeutics, Inc. | 866.631.4646 | clinicaltrials@introgen.com |
| Contact: Therapeutics, Inc. |
| United States, Colorado | |
| Unversity of Colorado Cancer Center | Recruiting |
| Aurora, Colorado, United States, 80045 | |
| Contact: Brittney Hines 720-848-0678 Brittany.Hines@uchsc.edu | |
| Principal Investigator: Madeleine Kane, MD | |
| United States, Kentucky | |
| Norton Healthcare Pavilion | Recruiting |
| Louisville, Kentucky, United States, 40202 | |
| Contact: Daniela Neamtu 502-629-4679 daniela.neamtu@nortonhealthcare.org | |
| Principal Investigator: John Hamm, MD | |
| United States, Maryland | |
| Cancer Center of GBMC | Recruiting |
| Baltimore, Maryland, United States, 21204 | |
| Contact: Lauren Titus 443-849-3285 ltitus@gbmc.org | |
| Principal Investigator: Marshall Levine, MD | |
| United States, South Carolina | |
| WJB Dorn VA Medical Center | Recruiting |
| Columbia, South Carolina, United States, 29209 | |
| Contact: Justin Reynolds 803-776-4000 ext 6074 justin.reynolds@va.gov | |
| Principal Investigator: William Hrushesky, MD | |
| United States, Texas | |
| Mary Crowley Medical Research Center | Recruiting |
| Dallas, Texas, United States, 75201 | |
| Contact: Arlen Waclawczyk 214-658-1985 awaclawczyk@mcmrc.com | |
| Principal Investigator: John Nemunaitis, MD | |
| Study Director: | Kerstin Menander, MD | |
| Study Chair: | Julie L Sicam, MT (ASCP) MSHS |
More Information
| Study ID Numbers: | T301 |
| Study First Received: | July 11, 2002 |
| Last Updated: | March 28, 2008 |
| ClinicalTrials.gov Identifier: | NCT00041613 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
Refractory Squamous Cell Carcinoma of the Head and Neck |
|
Epidermoid Carcinoma Carcinoma, Squamous Cell of Head and Neck Methotrexate Neoplasms, Squamous Cell |
Squamous Cell Carcinoma Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Carcinoma |
|
Neoplasms Neoplasms by Histologic Type Neoplasms, Squamous Cell |
Carcinoma, Squamous Cell Neoplasms, Glandular and Epithelial Carcinoma |
